PACB

$1.38

Market ClosedAs of Mar 17, 8:00 PM UTC

Pacific Biosciences of California, Inc.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.38
Potential Upside
5%
Whystock Fair Value$1.45
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technol...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$416.76M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.30
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-213.45%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
4.32

Recent News

StockStory
Mar 17, 2026

Fortrea, Alignment Healthcare, PacBio, DexCom, and Humana Stocks Trade Up, What You Need To Know

A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
StockStory
Mar 13, 2026

3 of Wall Street’s Favorite Stocks We Think Twice About

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 9, 2026

Why The PacBio (PACB) Investment Story Is Shifting As Analysts Cut Targets And Flag Risks

Pacific Biosciences of California is back in focus after analysts cut their price target to $1.50 from $2, while a separate fair value estimate was trimmed to $2.43 from $2.50. This shift is tied to an Underweight rating, along with fresh worries about near term demand for sequencing consumables, growth visibility, and a possible pause in orders ahead of new competitive launches. Read on to see what these changes might mean for you and how to track the evolving story around the stock. Analyst...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 6, 2026

PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know

A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
StockStory
Mar 4, 2026

Life Sciences Tools & Services Stocks Q4 Recap: Benchmarking PacBio (NASDAQ:PACB)

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.